Our-position
Potential access to selected medications for appropriate patients with serious, life-threatening diseases unable to participate in a clinical trial
Search
Win Fight Against Cancer
At Boehringer Ingelheim we are giving patients new hope. We are collaborating with the oncology community on a shared journey to deliver leading science.
GlyT1 Phase II results
Boehringer Ingelheim refocuses Gly-T1 inhibition brain research on schizophrenia
Metacam® Pets
meloxicam
Prascend
Symptomatic treatment of clinical signs associated with pituitary pars intermedia dysfunction (PPID; also known as equine Cushing’s disease).
A Unique Bond: friends in need
After suffering from a stroke, Phil’s connection with Valle helped change his life
Prevexxion™ RN
The vaccine is recommended for in ovo vaccination of 18 to 19-day-old embryonated chicken eggs to protect against the very virulent Marek’s disease.
Heartgard Plus
Prevents canine heartworm disease by eliminating the tissue stage of heartworm larvae for a month after infection, also treatment and control of roundworms and hookworms.
Have you heard of Pulmonary Fibrosis?
Pulmonary fibrosis is a devastating condition and can be an isolating disease.Taking charge of your heath starts with awareness and building your knowledge is a powerful way to show you care.
Cat care interview veterinarian Dr Susan Little
World-renowned feline healthcare specialist Dr. Susan Little shares her thoughts on latest trends in cat care.
Sifrol®
Symptomatic treatment of idiopathic Parkinson’s disease. It may be used as monotherapy or in combination with levodopa. Symptomatic treatment of idiopathic moderate to severe restless legs syndrome.
Livestock
Livestock
Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future
Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats
Translational Medicine in Immunology
Find out how translational medicine is helping bring transformational therapies to patients
Diabetic Retinopathy
Diabetic retinopathy affects 1 in 3 people with diabetes and is the leading cause of vision loss in adults of working age. It is a growing epidemic that is expected to increase as the incidence of diabetes escalates across the globe.
COVID-19 General Q&A
COVID-19 General Q&A
Combivent® Respimat®
A combination of a short-acting anticholinergic and beta-adrenergic for the management of reversible bronchospasms associated with obstructive airway diseases in patients requiring more than one bronchodilator.
The Research Process
The Research Process
sustainably fighting rabies info hub
Did you know that every nine minutes, rabies takes a human life? Find out how we support the elimination of this deadly disease.
Boehringer Ingelheim Opens New Scientific Office in Kenya as Part of its Commitment to Improve Human and Animal Health in Africa
Boehringer Ingelheim has officially opened its new scientific office in Nairobi, Kenya.
Behind the Lab
Delve behind the lab to see how our Retinal Health scientists are spearheading research into novel therapeutics to treat retinopathies.
Complications of Diabetic Retinopathy
Both Diabetic Macular Edema and Ischemia are maculopathies, they specifically affect the macula, responsible for high visual acuity.
Enterisol® Ileitis
For active immunisation of pigs from the age of three weeks against intestinal lesions caused by Lawsonia intracellularis infection and to reduce growth variability and weight loss associated with the disease.
Type 2 Diabetes and Risk of Viral Infections
In the current COVID-19 climate, it’s important for everyone to stay safe at home, particularly people living with pre-existing conditions such as type 2 diabetes or heart disease
NASH
NASH